Company: CERO
Filing Date: 2025-08-22
Form Type: 10-Q
Source: 0001213900-25-079898
Chunk: 3

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 10-Q
Item: Item 1
Chunk 3
---
630,775) 

    Change in fair value of earnout and derivative liabilities 
     -  
     2,900,000  
     -  
     4,700,000  
     320,117 
  
    Stock-based inducement expense 
     (707,300) 
     -  
     (863,550) 
     -  
     - 
  
    Interest income (expense), net 
     13,776  
     (16,977) 
     14,626  
     (31,411) 
     4,805 

    Total other income (expenses), net 
     (693,524) 
     2,699,583  
     (848,924) 
     4,627,037  
     324,922 
  
    Net loss 
     (5,417,315) 
     (2,448,654) 
     (10,523,246) 
     (4,176,137) 
     (572,211)
  
    Deemed dividend on Series A, B and C Preferred Stock 
     (24,700,374) 
     -  
     (24,964,518) 
     -  
     - 
  
    Deemed dividend related to Series C Common Warrants 
     -  
     -  
     (84,083) 
     -  
     - 
  
    Net loss attributable to common shareholders 
    $(30,117,689) 
    $(2,448,654) 
    $(35,571,847) 
    $(4,176,137) 
    $(572,211)

    Net loss per common share: 

    Basic and diluted 
    $(61.71) 
    $(302.32) 
    $(107.60) 
    $(531.35) 
    $(1,959.63)
  
    Weighted average common shares outstanding: 

    Basic and diluted 
     488,076  
     8,099  
     330,603  
     7,859  
     292 

See
accompanying notes to the condensed consolidated financial statements

Reflects
a 1-for-100 reverse stock split effective January 8, 2025 and